Neurogine Capital takes legal action against Emas Fintech

LABUAN, Malaysia - Feb. 2, 2021 - PRLog -- Neurogine Capital (L) Ltd, the developer and operator of Neurogine nTrade®, a money broking platform, has commenced civil proceedings against Emas Fintech Inc. (Emas Fintech). According Neurogine Capital managing director Chen Chee Peng, the suit was filed (WA-23CY-4-01/2021) earlier this week. Neurogine Capital is represented by its legal counsel, Messrs Anton & Chen.

"We have communicated to Emas Fintech and its chief executive officer Jason Kellady to cease the damage being inflicted to the reputation of Neurogine Capital," said Chen. "This includes the unauthorised use of our brand and logo to mislead the public, falsely portraying as if Neurogine Capital's guaranteeing extraordinary returns and other claims," he said.

Neurogine Capital's lead counsel Alex Anton Netto commented this legal action stemmed from Emas Fintech and Kellady repeatedly misleading Neurogine Capital with its false statements and claims when asked to clarify their business operations, abusing Neurogine Capital's brand and logo, resulting in economic losses and damaging Neurogine Capital's reputation.

Neurogine Capital terminated its relationship with Emas Fintech December 4, 2020, and its access to Neurogine Capital's money broking platform, branded as Neurogine nTrade®.

Following the termination, Kellady publicised videos on social platforms where he blamed Emas Fintech's losses due to alleged security breaches suffered by Neurogine nTrade®. Emas Fintech has ceased its operations, refused to refund its customers and its management has gone into hiding. "Kellady's claims have incited its customers to wrongly vent their anger on us. He has misled customers by accusing our platform, Neurogine nTrade®, as having been down or hacked. This is entirely false," said Chen.

"In fact, we are expanding and have accelerated our plans to offer individuals access to our service. We are now gradually expanding in controlled phases and plan to limit access to only 100 individuals. By this October, we will examine if we are ready to fully offer our Neurogine nTrade® to more individuals," explained Chen.

Neurogine Capital is a techfin which operates a money broking service, known as Neurogine nTrade® launched in 2020. "We initially served corporate users but our technology has sufficiently matured and we are ready to offer use of Neurogine nTrade® to individual users in other words the retail market."

Neurogine nTrade® is a highly secured platform and delivers price improvement with multi-pairing features, operating in the jurisdiction of Labuan International Business and Financial Centre and licensed by its regulator, Labuan Financial Services Authority, to provide Labuan money broking services.

ABOUT NEUROGINE CAPITAL
Neurogine Capital provides money broking services with its Artificial Intelligence-driven platform, Neurogine nTrade®, to offer multi pairing, multi routing and price transparency features with true price improvements.

http://www.ntrade.com.my